Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial

O'Mahony, Denis, Gudmundsson, Adalsteinn, Soiza, Roy L., Petrovic, Mirko, Jose Cruz-Jentoft, Alfonso, Cherubini, Antonio, Fordham, Richard, Byrne, Stephen, Dahly, Darren, Gallagher, Paul, Lavan, Amanda, Curtin, Denis, Dalton, Kieran, Cullinan, Shane, Flanagan, Evelyn, Shiely, Frances, Samuelsson, Olafur, Sverrisdottir, Astros, Subbarayan, Selvarani, Vandaele, Lore, Meireson, Eline, Montero-Errasquin, Beatriz, Rexach-Cano, Aurora, Correa Perez, Andrea, Lozano-Montoya, Isabel, Vélez-Díaz-Pallarés, Manuel, Cerenzia, Annarita, Corradi, Samanta, Soledad Cotorruelo Ferreiro, Maria, Dimitri, Federica, Marinelli, Paolo, Martelli, Gaia, Fong Soe Khioe, Rebekah and Eustace, Joseph (2020) Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial. Age and Ageing, 49 (4). pp. 605-614. ISSN 0002-0729

Full text not available from this repository. (Request a copy)

Abstract

BACKGROUND: Multi-morbidity and polypharmacy increase the risk of non-trivial adverse drug reactions (ADRs) in older people during hospitalization. Despite this, there are no established interventions for hospital-acquired ADR prevention. METHODS: We undertook a pragmatic, multi-national, parallel arm prospective randomized open-label, blinded endpoint (PROBE) controlled trial enrolling patients at six European medical centres. We randomized 1,537 older medical and surgical patients with multi-morbidity and polypharmacy on admission in a 1:1 ratio to SENATOR software-guided medication optimization plus standard care (intervention, n = 772, mean number of daily medications = 9.34) or standard care alone (control, n = 765, mean number of daily medications = 9.23) using block randomization stratified by site and admission type. Attending clinicians in the intervention arm received SENATOR-generated advice at a single time point with recommendations they could choose to adopt or not. The primary endpoint was occurrence of probable or certain ADRs within 14 days of randomization. Secondary endpoints were primary endpoint derivatives; tertiary endpoints included all-cause mortality, re-hospitalization, composite healthcare utilization and health-related quality of life. RESULTS: For the primary endpoint, there was no difference between the intervention and control groups (24.5 vs. 24.8%; OR 0.98; 95% CI 0.77-1.24; P = 0.88). Similarly, with secondary and tertiary endpoints, there were no significant differences. Among attending clinicians in the intervention group, implementation of SENATOR software-generated medication advice points was poor (~15%). CONCLUSIONS: In this trial, uptake of software-generated medication advice to minimize ADRs was poor and did not reduce ADR incidence during index hospitalization.

Item Type: Article
Uncontrolled Keywords: start criteria,adverse drug reactions,multi-morbidity,older people,polypharmacy,prevention,software,ageing,geriatrics and gerontology ,/dk/atira/pure/subjectarea/asjc/1300/1302
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 21 Jul 2020 01:38
Last Modified: 05 Aug 2020 23:49
URI: https://ueaeprints.uea.ac.uk/id/eprint/76207
DOI: 10.1093/ageing/afaa072

Actions (login required)

View Item View Item